VANCOPLUS


A patent protected novel antibiotic adjuvant entity (AAE) that works in multi drug resistant gram positive infections especially MRSA and hGISA type of Resistance of gram positive bacteria. Vancoplus is an Indian Innovation comprising of a third generation cephalosporin ceftriaxone and a glycopeptide antibiotic vancomycin along with non-antibiotic adjuvant L arginine for intravenous administration. It is a synergistic antimicrobial combination with marked in vitro activity against broad spectrum gram-positive and gram-negative bacteria.

Vancoplus Features

Concentration plus time dependent killing power of the components of Vancoplus makes bacterial cell more susceptible even to MDR gram-positive strains (MRSA, VISA, HGISA) & vancomycin-resistant pathogens.

Non-antibiotic adjuvant in Vancoplus stabilizes the incompatibility between vancomycin and ceftriaxone.

Enhances safety by reducing sequels due to toxin secretion during MRSA infections.

Breaks bacterial resistance by preventing biofilm formation, preventing drug efflux, restoring the substrate affinities for bacterial cell wall components.

Indications

  • Vancoplus is indicated for the treatment of serious or severe infections caused by susceptible strains of gram-positive (including methicillin-resistant strains) and gram-negative pathogens.
  • Complicated Skin and skin-structure infections (including cellulitis, myositis and necrotizing fasciitis)
  • Empirical therapy in meningitis, central nervous system (CNS) infection like brain abscess, suppurative intra cranial infections and Epidural abscess, Prophylaxis of shunt Infections

Product Presentation

1.5g or 3.0g dry powder for injection

Patent Granted

India Patent No. 263097
US Patent No. 7960337
EU Patent No. 1848413
Japan Patent No. 4918502

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to VRL India, its subsidiaries or affiliates. No use of any VRL India trademark, trade name, or trade dress in this site may be made without the prior written authorization of VRL India, except to identify the product or services of the company.

Back to Top